Treatment Initiation With Basal Insulin in Uncontrolled Type 2 Diabetes Patients on Oral Anti-Diabetic Agent (OAD) in Jordan
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms NEWLAN
- Sponsors Sanofi
- 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 15 Mar 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.